These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 7913936

  • 1. Frequent RET protooncogene mutations in multiple endocrine neoplasia type 2A.
    Quadro L, Panariello L, Salvatore D, Carlomagno F, Del Prete M, Nunziata V, Colantuoni V, Di Giovanni G, Brandi ML, Mannelli M.
    J Clin Endocrinol Metab; 1994 Aug; 79(2):590-4. PubMed ID: 7913936
    [Abstract] [Full Text] [Related]

  • 2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P.
    Verh Dtsch Ges Pathol; 1995 Aug; 79():L-LV. PubMed ID: 8600671
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.
    Frank-Raue K, Höppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R, Rendl J, Deckart HF, Ritter MM, Hampel R, Klempa J, Scholz GH, Raue F.
    J Clin Endocrinol Metab; 1996 May; 81(5):1780-3. PubMed ID: 8626834
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G, Domené HM, Iorcansky S, Barontini M.
    Medicina (B Aires); 1998 May; 58(2):179-84. PubMed ID: 9706252
    [Abstract] [Full Text] [Related]

  • 8. Mutations in the RET protooncogene in sporadic pheochromocytomas.
    Lindor NM, Honchel R, Khosla S, Thibodeau SN.
    J Clin Endocrinol Metab; 1995 Feb; 80(2):627-9. PubMed ID: 7852530
    [Abstract] [Full Text] [Related]

  • 9. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain.
    Bugalho MJ, Frade JP, Santos JR, Limbert E, Sobrinho L.
    Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. RET proto-oncogene point mutations in sporadic neuroendocrine tumors.
    Komminoth P, Roth J, Muletta-Feurer S, Saremaslani P, Seelentag WK, Heitz PU.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2041-6. PubMed ID: 8964826
    [Abstract] [Full Text] [Related]

  • 12. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
    Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F, Martino E, Romeo G, Pacini F.
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
    [Abstract] [Full Text] [Related]

  • 13. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
    Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T, Takahashi M.
    Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A single missense mutation in codon 918 of the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Maeda S, Namba H, Takamura N, Tanigawa K, Takahashi M, Noguchi S, Nagataki S, Kanematsu T, Yamashita S.
    Endocr J; 1995 Apr; 42(2):245-50. PubMed ID: 7627269
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P, Muletta-Feurer S, Soltermann A, Gemsenjäger E, Bürgi H, Staub JJ, Schönle E, Fried M, Vetter W, Spinas GA, Heitz PU.
    Schweiz Med Wochenschr; 1996 Aug 06; 126(31-32):1329-38. PubMed ID: 8765374
    [Abstract] [Full Text] [Related]

  • 18. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma.
    Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G.
    Nature; 1994 Jan 27; 367(6461):375-6. PubMed ID: 7906866
    [Abstract] [Full Text] [Related]

  • 19. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE, Mello MP, Elias LL, Lau IF, Maciel LM, Moreira AC, Castro M.
    Horm Metab Res; 2002 Apr 27; 34(4):202-6. PubMed ID: 11987030
    [Abstract] [Full Text] [Related]

  • 20. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.
    Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells SA.
    Hum Mol Genet; 1993 Jul 27; 2(7):851-6. PubMed ID: 8103403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.